MarketPulse

vaccine

2 articles
The Motley FoolThe Motley Fool··Adria Cimino

Moderna's 70% Rally Fuels Debate: Growth Story or Overheated Biotech?

Moderna stock surges 70% in 2026 on vaccine and cancer therapy pipeline expansion, but $2.8B losses amid $1.9B revenue temper bullish sentiment.
MRNAbiotechoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Shingles Market Set for Double-Digit Growth as Aging Populations Drive Vaccine Demand Through 2036

Shingles vaccine market poised for robust growth through 2036 driven by aging populations, vaccine adoption, and emerging candidates challenging market leader SHINGRIX.
GSKclinical trialsmarket growth